Please assess the completion status of the following clinical trial:

Trial Title: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Over 21 years of age~* Must sign informed consent, witnessed, and dated prior to entry~* The participant has an increased risk for developing breast cancer which may include; Atypical Ductal Hyperplasia (ADH), Lobular Carcinoma in situ (LCIS), and/or Atypical Lobular Hyperplasia (ALH)~* Performance Status: ECOG 0-1 unless mobility is limited from chronic physical handicap~* No clinical evidence of other malignancies (except Basal Cell carcinoma)~* Complete blood count, differential and platelet count must be within normal limits (WNL) or verified by the study chair to be related to conditions not interfering with normal health status~* Adequate hepatic and renal function (these must be WNL or verified by study chair to be related to conditions not interfering with normal health status)~* Normal fasting glucose~* No history of diabetes~* Medically and Psychologically able to comply with all study requirements~* Accessible to Follow up~Exclusion Criteria~* Less than 21 years of age~* Known invasive breast cancer of any type~* Bilateral prophylactic mastectomy~* Prior malignancy of any type that occurred less than 5 years previously, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Existing non-malignant disease that would preclude the administration of SOM230~* Pregnancy: All subjects will have a beta human chorionic gonadotropin (b-hCG) serum pregnancy test to rule out pregnancy, a history will also be taken to make certain that recent sexual exposure does not put them at risk for pregnancy. If so a second serum pregnancy test will be done. Volunteers will be asked to use barrier contraception during study.~* Tamoxifen or other preventive measures within 6 months~* Serious Psychiatric condition or addictive disorder~* Diabetes or elevated fasting blood sugar~* Inability to inject medication or test for finger stick glucose~* Symptomatic gallstones or known gall bladder disease~* History of cholecystitis without cholecystectomy~* Electrolyte abnormalities (particularly hypokalemia or hypomagnesemia)~QT related exclusion criteria~* QTcF at screening \> 450 msec.~* History of syncope or family history of idiopathic sudden death.~* Sustained or clinically significant cardiac arrhythmias.~* Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block.~* Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure~* Concomitant medication(s) known to increase the QT interval.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ADH, ALH, LCIS, SOM 230 (Type: EXPERIMENTAL): Women who meet eligibility criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete